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http://dx.doi.org/10.1016/j.ccr.2014.07.010SUMMARYSplicing dysregulation is one of the molecular hallmarks of cancer. However, the underlying molecular mech-
anisms remain poorly defined. Here we report that the splicing factor RBM4 suppresses proliferation and
migration of various cancer cells by specifically controlling cancer-related splicing. Particularly, RBM4 reg-
ulates Bcl-x splicing to induce apoptosis, and coexpression of Bcl-xL partially reverses the RBM4-mediated
tumor suppression. Moreover, RBM4 antagonizes an oncogenic splicing factor, SRSF1, to inhibit mTOR acti-
vation. Strikingly, RBM4 expression is decreased dramatically in cancer patients, and the RBM4 level corre-
lates positively with improved survival. In addition to providing mechanistic insights of cancer-related
splicing dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potential and
clinical values as a prognostic factor.INTRODUCTION
As one of the most prevalent mechanisms of gene regulation,
alternative splicing (AS) plays a vital role in the intricate regula-
tion of protein function, and splicing dysregulation is closely
associated with human cancers (David and Manley, 2010; Ol-
tean and Bates, 2013; Venables, 2006). Accumulating evidence
suggests that aberrant AS elicits control over major hallmarks
of cancer, including apoptosis (Schwerk and Schulze-Osthoff,
2005), epithelial-mesenchymal transition (Warzecha et al.,
2010), and tumor invasion and metastasis (Ghigna et al.,
2008). The ‘‘cancerous’’ splicing variants of specific genes
can serve as molecular markers of cancer (e.g., CD44 and
WT1) (Venables et al., 2008) or directly mediate cancer patho-
genesis (e.g. BRCA1 and p53) (Venables, 2006). However,Significance
Aberrant splicing is closely associated with human cancers. Ho
are largely unknown. Investigating splicing factors that play vit
geting of deregulated splicing and open new avenues for canc
ated splicing regulation pathway that is closely related to can
suppresses tumor progression by balancing the pro- and antia
nizing the oncogenic splicing factor SRSF1. The clinical relevan
a detailedmechanism of cancer-related splicing dysregulation
tic potential.
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splicing in cancer is still limited.
AS is generally regulated by multiple cis-elements that recruit
splicing factors to affect adjacent splice sites (ss) via various
mechanisms (Matera and Wang, 2014; Matlin et al., 2005;
Wang and Burge, 2008). Common splicing factors include
serine/arginine-rich (SR) proteins that promote splicing by bind-
ing to exons but inhibit splicing by binding to introns (Erkelenz
et al., 2013; Wang et al., 2013) and heterogeneous nuclear ribo-
nucleoproteins (hnRNPs) that positively or negatively control
splicing in different pre-mRNA regions (Wang et al., 2012). The
expression level, localization, and activity of splicing factors
generally determine splicing outcomes in different tissues and
cellular conditions. Therefore, altered splicing factor activity is
believed to be a main cause of splicing dysregulation in cancerwever, themechanistic details underlying these connections
al roles in cancer progression would enable therapeutic tar-
er therapy. Here we systematically dissect an RBM4-medi-
cer progression. We uncover that the splicing factor RBM4
poptotic signals through splicing regulation and by antago-
ce of such regulation is also revealed. This study represents
and establishes RBM4 as a tumor suppressor with therapeu-
.
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is a proto-oncogene that controls splicing of several cancer-
related genes, including those in the mammalian target of rapa-
mycin (mTOR) pathway (Blaustein et al., 2005; Karni et al., 2007).
Because splicing dysregulation is one of themolecular hallmarks
of cancer (Oltean and Bates, 2013), specifically targeting splicing
factors opens potential new avenues for cancer therapy (Dehm,
2013).
We have previously identified RNA-binding motif 4 (RBM4) as
a binding factor for a group of intronic splicing regulatory ele-
ments that control the AS of human genes (Wang et al., 2012).
Initially identified by sharing the nuclear import pathway with
SR proteins, RBM4 shuttles between the cytoplasm and nucleus
but is mostly found in nuclear speckles (Lai et al., 2003), where
most splicing events occur. RBM4 has been shown consistently
to control the AS of Tau and a-tropomyosin (Kar et al., 2006; Lin
and Tarn, 2005). In addition, RBM4 has been found to affect
translation (Lin and Tarn, 2009; Uniacke et al., 2012). Multiple
physiological functions have been reported for RBM4, including
mediating differentiation of muscle and pancreas cells (Lin et al.,
2007; Lin et al., 2013). However, the involvement of RBM4 in
tumorigenesis has not been reported. Here we systematically
analyzed RBM4-mediated changes of the transcriptome and as-
sessed the role of RBM4 in cancer progression.
RESULTS
RBM4 Is a Sequence-Specific Splicing Inhibitor that
Regulates Various AS Events
Previously we identified several groups of intronic splicing regu-
latory elements and their cognate splicing factors (Wang et al.,
2012, 2013). We demonstrated that, of those factors, RBM4 spe-
cifically binds to the GTAACG motif to inhibit splicing from in-
trons (Wang et al., 2012). In addition, another RBM4 binding
motif (CGG repeats) was also identified with crosslinking immu-
noprecipitation sequencing (Uniacke et al., 2012). Because AS is
usually regulated in a context-dependent manner, we sought to
examine how RBM4 controls splicing when bound to distinct
RNA motifs in different pre-mRNA contexts.
We generated four splicing reporters with candidate RBM4-
binding motifs (GTAACG or CGGCGG) inserted in different re-
gions to examine whether RBM4 can specifically alter their
splicing (Figure 1). First, we found that RBM4 specifically in-
hibited the inclusion of a cassette exon containing its cognate
binding sites, whereas the control reporter was not affected (Fig-
ure 1A). Furthermore, RBM4 specifically suppressed the inclu-
sion of a reporter exon with a downstream RBM4 binding site
(Figure 1B). These results suggest that RBM4 functions as a gen-
eral splicing inhibitor to specifically suppress splicing from both
exonic and intronic contexts. Such activities are in contrast to
DAZAP1, a splicing factor that recognizes the same GTAACG
site but functions as a splicing activator (Choudhury et al.,
2014). Interestingly, DAZAP1 does not affect splicing of exons
containing a nearby CGGCGG site (Figures S1A and S1B avail-
able online), suggesting a partial overlap of binding specificity
and an incomplete functional competition between RBM4 and
DAZAP1.
Using splicing reporters containing RBM4-binding motifs be-
tween alternative 50 ss or 30 ss, we found that RBM4 reducedCathe use of the downstream 50 ss (Figure 1C) or upstream 30 ss
(Figure 1D). The inhibition of distal alternative ss is again
sequence-specific because RBM4 showed no effect on the con-
trol reporters (Figures 1C and 1D). Consistently, knockdown of
RBM4with small hairpin RNA had opposite effects by increasing
exon inclusion of the same splicing reporters that contain RBM4-
binding sites in various locations (Figures S1C–S1F). In addition,
similar results were obtained in a different cell type (e.g. HeLa
cells), indicating that the splicing regulation activity of RBM4 is
not limited to a specific cell line (Figures S1G–S1J). Together,
these data demonstrate that RBM4 is a general splicing inhibitor
that controls different types of AS when specifically binding to
pre-mRNA.
Like many canonical splicing factors, RBM4 has a modular
domain configuration. The N terminus contains two RNA recog-
nition motifs (RRMs) and a CCHC-type zinc finger that can
specifically bind RNAs, whereas the C terminus contains a
low-complexity region (i.e. Ala-rich stretches) that can interact
with other proteins (Lin and Tarn, 2009) (Figure 1E). To examine
whether RBM4 has a modular role in splicing regulation, we
fused the full-length N- or C-terminal fragments of RBM4 to
another RNA binding domain, Pumilio/FBF (PUF) (Wang et al.,
2009). We coexpressed the fusion proteins with splicing re-
porters containing cognate PUF targets inside an alternative
exon (Figure 1F) or at a downstream intron (Figure 1G) and
measured how splicing is affected. As expected, tethering the
full-length RBM4 to a target site inside an alternative exon sup-
pressed exon inclusion. Surprisingly, tethering either the N- or
C-terminal domain of RBM4 partially inhibited exon inclusion
(Figure 1F), suggesting that the RNA binding fragment and the
low-complexity domain both serve as functional modules.
Such an effect is sequence-specific because these fusion pro-
teins had no effect on control reporters with a noncognate target.
Consistently, the full-length RBM4 inhibited exon inclusion when
tethered downstream of a cassette exon (Figure 1G). Interest-
ingly, the N-terminal fragment partially inhibited splicing from
an intron, whereas the C terminus showed a slight splicing-inhib-
itory activity (Figure 1G). Together, the N-terminal RNA-binding
fragment and the C-terminal low-complexity domain of RBM4
function cooperatively to control different types of AS events in
a sequence-specific manner.
Global Regulation of the Transcriptome by RBM4
in Cancer-Related Genes
To gain further insights into RBM4-regulated AS events and,
thereby, its physiological functions, we conducted high-
throughput sequencing of mRNA (mRNA-seq) with H157 cells
expressing RBM4. With 80 million 100-nt paired-end reads,
we identified 473 RBM4-regulated AS events with an obvious
change of percent-spliced-in (PSI) values (PSIR 0.15). Figure 2A
shows the read tracks of two examples. We found that various
types of AS can be regulated by RBM4, including skipped
exon (SE), alternative 50 ss exon (A5E), alternative 30 ss exon
(A3E), retained intron (RI), mutually exclusive exons (MXE), and
tandem UTR (TUTR) (Figure 2B; Table S1). Subsequent analysis
indicated that most of the AS events were negatively regulated
byRBM4 (decreasedPSI value byRBM4expression) (Figure 2C),
consistent with our finding that RBM4 suppressed splicing when
binding directly to its pre-mRNA targets (Figures 1A–1D).ncer Cell 26, 374–389, September 8, 2014 ª2014 Elsevier Inc. 375
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mRNAs by extracting the sequences near the RBM4-regulated
SEs or between alternative 50 ss of A5E. The relative abundance
of RBM4 binding motifs (GTAACG and CGGCGG) in these re-
gions was compared with control exons unaffected by RBM4
(Fairbrother et al., 2002). We found that RBM4-binding motifs
are enriched near the SEs or A5Es negatively regulated by
RBM4 (Figure 2D), consistent with the model that RBM4 directly
recognizes these pre-mRNAs to control splicing. The AS events
apparently promoted by RBM4 are likely due to indirect effects
because these exons lack known RBM4 binding motifs
(Figure 2D).
When analyzing cellular functions of RBM4-regulated AS
events using gene ontology, we found that RBM4 affects genes
in the RNA processing pathway, including translation control,
RNA processing, and the mRNA metabolic process (Figure 2E).
Such functional enrichment is not surprising because RBM4 is an
RNA binding factor known to regulate splicing and translation.
Intriguingly, RBM4 targets are also enriched with cancer-related
functions such as regulation of the NF-kB cascade and cell cy-
cle. In addition, several RBM4-regulated AS events were found
to regulate the apoptotic pathway. Although this enrichment of
apoptosis is slightly below our significance cutoff, the changes
of PSI value are fairly large and, therefore, may have significant
functional consequences. Many of the RBM4-regulated splicing
targets were functionally connected into well linked interaction
networks, as judged by the Search Tool for the Retrieval of Inter-
acting Genes/Proteins (STRING) (Figure 2F). As expected, two
large subgroups of RBM4 targets contain genes involved in
translation control and RNA processing. Surprisingly, the other
subgroup includes many genes involved in cell migration and
adhesion (Figure 2F). Taken together, these results suggest
that the biological processes affected by RBM4 are related to
apoptosis, proliferation, migration, and tumorigenesis.
We subsequently validated mRNA-seq results by measuring
the splicing change of ten newly identified targets that were
selected arbitrarily to include genes with a cancer-related func-
tion.We confirmed that RBM4 either positively or negatively con-
trols all endogenous AS events tested (Figure 2G) and that the
relative changes of PSIs obtained from RT-PCR are highly corre-
lated to those observed by mRNA-seq (Figure S2A; R2 = 0.6).
These events were also validated in another cell line (HeLa) (Fig-
ure S2B), suggesting that RBM4 can regulate AS with consistent
activity across different cell types. In addition, we found that
knockdown of RBM4 caused opposite changes of splicing inFigure 1. Splicing Regulation by RBM4
(A) The RBM4 binding sites and a control (GAATTG) were inserted into splicing re
vector (mock) into 293T cells. Splicing changes were examined by electrophores
(B) The same set of sequences as analyzed in (A) was inserted downstream of a
(C and D) The same set of RBM4-binding sequences as analyzed in (A) was inserte
30 ss (D), and splicing changes were measured as in (A).
(E) Schematics of RBM4 domains. The R1R2Z fragment contains two RRM doma
stretch.
(F andG) Different RBM4 fragments were fused to a PUF domain, PUF(3-2), that sp
splicing reporter containing a PUF binding site or a control (Ctl) site in a cassette ex
(A). The arrowhead indicates a nonspecific product (F).
In panels measuring changes in splicing, expression of exogenous protein was co
Three independent experiments were conducted, with the mean ± SD of PSIs plo
See also Figure S1.
Caendogenous RBM4 targets, further confirming the reliability of
our analyses (Figures S2C and S2D).
We also analyzed how RBM4 affects global gene expression.
We identified 185 genes with significant expression change (>2-
fold with adjusted p < 0.05) (Table S2). These genes are associ-
ated significantly with cancer-related functions, as judged by
gene ontology (including DNA replication, chemotaxis, cell pro-
liferation, response to wounding, cell cycle, and cell migration;
Figure 2H), again suggesting that RBM4 is involved in cancer
cell proliferation and migration. Many RBM4-regulated genes
were also connected functionally into a densely linked network
that contains genes involved in regulating cell proliferation,
wound healing, cell cycle, and DNA damage (Figure 2I). The
selected RBM4 targets were further validated with real-time
RT-PCRs (Figure 2J). Taken together, these data imply that
RBM4 may be a key regulator of cell proliferation and migration,
therefore controlling cancer progression.
RBM4 Inhibits Cancer Cell Proliferation and Migration
To examine this possible role of RBM4 in cancer progression, we
stably expressed RBM4 in a panel of human cancer cells,
including H157 (lung cancer), MDA-MB-231 (breast cancer),
SKOV3 (ovarian cancer), Panc-1 (pancreatic cancer), HepG2
(liver cancer), and PC-3 (prostate cancer) (Figure S3A). Strikingly,
in all cancer cells tested, RBM4 inhibited anchorage-dependent
or anchorage-independent growth, as judged by colony forma-
tion or soft agar assay (Figure 3A). In addition, RBM4 inhibited
migration of these cells in a wound healing assay (Figure 3B).
Together, the inhibition of cancer cell proliferation and migration
by RBM4 suggests that it may function as a tumor suppressor.
We further analyzed how RBM4 affects cancer progression
using non-small cell lung carcinoma (NSCLC) cells, which repre-
sent one of the most prevalent human cancers. The RBM4 levels
were decreased markedly in a panel of NSCLC cells compared
with normal bronchial cells (Figure 3C). Consistently, when re-
expressed in a NSCLC cell line, H157, RBM4 significantly in-
hibited cell growth (Figure 3D; p = 0.02 by t test). Similar growth
inhibition by RBM4 was observed in 293T cells (Figures S3B and
S3C). Interestingly, although both the N- and C termini of RBM4
partially regulate splicing, lung cancer cells expressing either
domain (amino acids (aa) 1–177 or aa 178–364 of RBM4) dis-
played normal growth rates (Figure 3E), suggesting that both do-
mains are required to suppress tumorigenesis.
To further assesswhether RBM4 affects cancer growth in vivo,
we determined whether RBM4 re-expression can suppressporter pGZ3 and cotransfected with the RBM4 expression vector or an empty
is of RT-PCR products.
cassette exon in the pZW2C reporter to measure splicing changes as in (A).
d into the splicing reporters between two tandem sites with competing 50 (C) or
ins and a zinc finger domain. The polyalanine fragment contains a polyalanine
ecifically binds to its target RNA. The fusion proteins were cotransfected with a
on (F) or at a downstream intron (G), and splicing changes weremeasured as in
nfirmed by western blot analyses. Tubulin served as a protein loading control.
tted below the representative gels. *p < 0.05 as calculated by Student’s t test.
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luc-RBM4 cells and control cells with lentiviral vectors and
injected them subcutaneously into the flanks of nude mice (left
flank, RBM4; right flank, control). The growth of tumors was
measured every 3 days for 5 weeks, and xenograft tumors
were removed for final analysis. Consistent with the in vitro re-
sults, cells expressing RBM4 developed smaller tumors
compared with control cells (Figures 3F and 3G). In addition,
the xenograft tumors with RBM4 re-expression grew much
slower than controls (Figure 3H), suggesting that RBM4 substan-
tially inhibits cancer progression in vivo. Together, these findings
indicate that RBM4 is a potent tumor suppressor that inhibits
lung cancer progression both in cultured cells and in a tumor
xenograft model.
RBM4 Induces Cancer Cell Apoptosis via Regulating AS
of Bcl-x
To determine the mechanisms of how RBM4 affects cancer pro-
gression, we focused on an RBM4 target gene, Bcl-x, an
apoptosis regulator that produces two splicing isoforms with
opposite functions. By alternative use of 50 ss, Bcl-x is spliced
as an antiapoptotic isoform (Bcl-xL) or a proapoptotic isoform
(Bcl-xS) (Adams and Cory, 2007). RBM4 expression appeared
to shift Bcl-xL into Bcl-xS (Figure 2G). Such a shift requires an
entire RBM4 because neither the N terminus nor the C terminus
can affect Bcl-x splicing by itself (Figure S4A).We identified a po-
tential RBM4 binding site (CGGCGG) between the two alterna-
tive 50 ss (Figure 4A), implying that RBM4 may control splicing
through binding directly to Bcl-x pre-mRNA. Consistently, with
an RNA immunoprecipitation assay, we found that RBM4 indeed
binds directly to the endogenous Bcl-x pre-mRNA but not the
control pre-mRNA of another alternatively spliced apoptotic
gene (Mcl1) (Figure 4B). Using a splicing reporter containing
Bcl-x pre-mRNA, we found that RBM4 binding is indeed depen-
dent on the CGGCGG site because mutation of this site abol-
ished RNA-protein interaction (Figure 4C). Replacing the
mutated sequence with the other RBM4-binding site (GTAACG)
restored the interaction, confirming that RBM4 directly recog-
nizes the exon extension region of Bcl-x.
In addition to H157 cells, an inducible expression of RBM4
also shifted splicing of Bcl-x in 293 cells (Figure 4D). This shift
caused a rapid and robust decrease of Bcl-xL protein, as judgedFigure 2. Global Splicing and Transcriptional Regulation by RBM4
(A) Examples of alternative exons affected by RBM4. Genes were chosen to repre
reads are indicated.
(B) Quantification of the different AS events affected by RBM4.
(C) The relative fraction of each AS event affected positively or negatively by RB
(D) Relative enrichment of the indicated RNAmotifs bound by RBM4. Enrichment s
AS events unaffected by RBM4. AS events with increased or decreased PSI valu
(E) Gene ontology of RBM4-regulated AS targets. Fisher exact p values were plo
(F) Functional association network of RBM4-regulated AS targets. The genes in
according to their functions.
(G) Validation of different types of RBM4-regulated AS events by semiquantitat
mean ± SD of PSIs from three experiments were plotted (p values were calculat
(H) Gene ontology analyses of RBM4-regulated gene expression events. Fisher e
(I) The functional association networks of RBM4-regulated genes were analyzed
(J) Validation of gene expression changes by real-time RT-PCR. The mean ± SD
calculated by paired Student’s t test.
See also Figure S2 and Tables S1 and S2.
Caby western blot analysis (Figure S4B). To determine whether the
binding by RBM4 is responsible for the observed splicing shift,
we cotransfected RBM4 with a series of Bcl-x reporters contain-
ing various mutations near the alternative 50 ss (Figure 4A). We
found that RBM4 shifted the splicing of the wild-type reporter
by reducing Bcl-xL and that such a regulation was not affected
by three exonic mutations (mutations 1–3) (Figure 4E). However,
the mutation of the RBM4 binding site (mut 4) completely abol-
ished the splicing regulation through RBM4, indicating that the
RBM4 binding motif (CGGCGG) is indeed responsible for the
Bcl-x splicing switch. Importantly, replacing CGGCGG with
another RBM4 binding site (mut 5) restored the regulation by
RBM4 (Figure 4E), suggesting that binding of RBM4 to Bcl-x
pre-mRNA is sufficient to shift splicing.
The two splicing isoforms of Bcl-x have opposite functions in
controlling apoptosis (Adams and Cory, 2007). Bcl-xL is the pre-
dominant isoform in cancer, and RNAi of Bcl-xL has been shown
to induce apoptosis in several cancer cell lines (Mercatante et al.,
2001; Zhu et al., 2005). We found that expression of RBM4 in
H157 cells substantially reduced the level of Bcl-xL protein, re-
sulting in the cleavage of caspase 3 and poly-ADP-ribose poly-
merase (PARP), two molecular markers of apoptosis (Figure 4F).
Consistently, RBM4 dramatically increased spontaneous
apoptosis, as judged by flow cytometry (Figure 4G; Figure S4C).
These results support the model that sequence-specific binding
of RBM4 to Bcl-x pre-mRNA shifts its splicing from antiapoptotic
Bcl-xL to proapoptotic Bcl-xS, thereby promoting cancer cell
death.
RBM4 Suppresses Tumor Progression in Part through
Bcl-x
Because RBM4 may inhibit cancer proliferation through modu-
lating Bcl-x splicing, we next examined whether coexpression
of Bcl-xL, but not other similar apoptotic regulators, can overturn
the tumor suppressor activity of RBM4. We stably transfected
the parental H157 line containing re-expressed RBM4 with Bcl-
xL or another apoptotic inhibitor, Mcl-1 (Figure 5A), generating
a cell line with a partially restored Bcl-xL/Bcl-xS ratio and
reduced PARP cleavage (Figure 5B). We found that cells
expressing RBM4/Bcl-xL grew much faster than those ex-
pressing RBM4 alone, although the growth rate was not fully
restored compared with the control (Figure 5C). However, cellssent both an increase and a decrease of PSI, and the numbers of exon junction
M4.
cores were computed by comparing RBM4-regulated SEs or A5Eswith control
es upon RBM4 expression were analyzed separately.
tted for each enriched functional category.
(E) were analyzed using the STRING database, and subgroups are marked
ive RT-PCR using H157 cells transfected with RBM4 or control vectors. The
ed by paired Student’s t test).
xact p values were plotted for each category.
using the STRING database, with subgroups marked by their functions.
of relative fold changes from triplicate experiments were plotted, with p values
ncer Cell 26, 374–389, September 8, 2014 ª2014 Elsevier Inc. 379
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with cells expressing RBM4 alone (Figure 5C), indicating that
such phenotypical rescue is specific for Bcl-xL. In addition, can-
cer cells expressing RBM4/Bcl-xL migrated significantly faster
than cells expressing RBM4 alone or RBM4/Mcl-1 (Figure 5D),
again suggesting that restoring the Bcl-xL level partially reversed
the RBM4 phenotype. Consistently, the xenograft tumors gener-
ated from RBM4/Bcl-xL cells were significantly larger than those
from RBM4/vector cells, indicating that reducing the Bcl-xL level
is partially responsible for RBM4-mediated tumor suppression
in vivo (Figure 5E). This phenotypic rescue is robust and statisti-
cally significant, although it could not fully restore tumor progres-
sion, probably because of the partial reversal of the Bcl-xL/
Bcl-xS ratio (Figure 5B).
We further applied a specific Bcl-xL inhibitor (WEHI-539) in
cells expressing RBM4 and examined its effect on cell growth.
Consistent with a previous report (Lessene et al., 2013),
WEHI-539 did not significantly affect the viability of control cells.
However, WEHI-539 treatment inhibited the proliferation of
RBM4-expressing cancer cells compared with untreated cells
(Figures 5F and 5G). Such an apparent synergistic effect may
reflect two mechanisms that are not mutually exclusive:
(1) Through splicing regulation, RBM4 reduces the level of Bcl-
xL to the extent where the WEHI-539 can have a detectable
effect; (2) RBM4 inhibits cell proliferation through other mecha-
nisms in addition to reducing antiapoptotic Bcl-xL, whereas
WEHI-539 specifically inhibits Bcl-xL. By targeting parallel pro-
survival pathways, the combination of RBM4 andWEHI-539 syn-
ergistically suppressed cancer cell proliferation.
Consistently, we found an increased expression of Bcl-xL in
lung cancers, breast cancers, and pancreatic cancers, which is
correlated inversely to the RBM4 level (Figure 5H; Figures S5A
and S5B). This finding further supports the hypothesis that
RBM4 inhibits tumor progression (at least partially) via controlling
Bcl-x splicing.
RBM4 Antagonizes Oncogenic SRSF1 to Inhibit mTOR
Activation
Although our data clearly demonstrate that RBM4 suppresses
cancer progression by modulating Bcl-x splicing, this may not
be the only mechanism because coexpression of Bcl-xL partially
reversed the phenotype of RBM4. To eliminate the apoptosis ef-Figure 3. RBM4 Inhibits Cancer Progression
(A) RBM4 effects on the proliferation of various cancer cells, including H157, M
transfected with RBM4 or a vector control and analyzed by colony formation (top
triplicate, with mean ± SD of relative colony numbers plotted (p values were calcul
Scale bars, 100 mm.
(B) Different cancer cell lines expressing RBM4 or a vector control were analyzed
experiments, with mean ± SD plotted (p values were calculated by Student’s t te
(C) Levels of RBM4 in the indicated NSCLC cell lines and normal bronchial cells
(D) H157 cells stably expressing RBM4 or a vector control were grown for 9 day
compared to day 0. The mean ± SD from three experiments was plotted.
(E) H157 cells expressing full-length (FL) RBM4 or the N-terminal (N-term) or C-te
Representative pictures of the whole plates from triplicate experiments are sho
calculated by Student’s t test.
(F) H157-luc-RBM4 and control cells were injected subcutaneously into the lef
monitored by bioluminescence imaging on days 3 and 35, and pictures of two re
(G) Pictures of the tumors removed after 35 days.
(H) The average sizes of xenograft tumors measured every 3 days (n = 7, error b
See also Figure S3.
Cafect, we treated cells with a pan-caspase inhibitor, carboben-
zoxy-valyl-alanyl-aspartyl (Z-VAD). We found that, even when
the apoptosis was inhibited strongly (Figure 6A), proliferation
and migration of cancer cells were still suppressed significantly
by RBM4 (Figure 6B). This observation suggests that RBM4
might also inhibit cancer progression through other mechanisms
besides regulating apoptosis.
It has been reported previously that the general splicing factor
SRSF1 functions as a proto-oncogene to transform rodent fibro-
blasts (Karni et al., 2007). We found that RBM4 interacted with
SRSF1 in a coimmunoprecipitation assay (Figure S6A). Remark-
ably, RBM4 can reduce the protein level of SRSF1 in a dose-
dependent manner (Figure 6C). Such inhibition is specific to
SRSF1 because two other splicing factors, DAZAP1 and
hnRNPA1, were not affected (Figure 6C). Similar results were
also obtained in a cell line with inducible expression of RBM4
(Figure S6B). Since SRSF1 is a well characterized oncogenic
factor to promote tumorigenesis through multiple pathways (An-
czuko´w et al., 2012; Karni et al., 2007), our observation suggests
that RBM4 may also inhibit cancer progression by antagonizing
SRSF1.
SRSF1 is known to control multiple AS events that promote
tumorigenesis (Anczuko´w et al., 2012; Karni et al., 2007). For
example, BIN1 is a tumor suppressor that binds to MYC (Saka-
muro et al., 1996), and SRSF1 promotes inclusion of BIN1 exon
12a to generate a BIN1+12 isoform that lacks tumor suppressor
activity (Karni et al., 2007). SRSF1 also inhibits the exclusion of
exon 11 in RON, generating ROND11, which promotes cell
migration and invasion (Anczuko´w et al., 2012). We examined
whether RBM4 could affect the splicing of cancer-related
SRSF1 targets using cells stably expressing SRSF1, RBM4,
or SRSF1/RBM4. As expected, RBM4 regulated splicing of
both BIN1 and RON in an opposite fashion as SRSF1, shifting
their splicing toward antioncogenic isoforms (Figure 6D;
Figure S6C).
SRSF1 has also been reported to activate the mTOR pathway
by increasing phosphorylation of S6K1 and 4E-BP1 as well as by
promoting oncogenic S6K1 splicing isoform 2 (Karni et al., 2007;
Karni et al., 2008). Coexpression of RBM4 with SRSF1 substan-
tially inhibited SRSF1-induced mTOR activation, as judged by
the dramatic reduction in the phosphorylation of S6K1 and 4E-
BP1 (Figure 6E). However, phosphorylation of two upstreamDA-MB-231, SKOV3, Panc-1, HepG2, and PC-3 cells. The cells were stably
panels) or soft agar (bottom panels) assays. All experiments were performed in
ated by Student’s t test). Images of the whole plate are shown in the top panels.
by wound healing assay. Percent of wound closure was measured in triplicate
st). Scale bar, 200 mm.
were measured by western blot analysis.
s, with cell numbers counted every 2 days. The changes of cell numbers were
rminal (C-term) fragments of RBM4 were analyzed by colony formation assay.
wn. The mean ± SD of relative colony numbers were plotted, with p values
t and right flanks of seven nude mice. The growth of xenograft tumors was
presentative mice are shown.
ars indicate SD, p < 0.05 by Student’s t test).
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Figure 4. RBM4 Regulates Bcl-x Splicing to Induce Apoptosis
(A) Schematic of Bcl-x pre-mRNA with the potential RBM4-binding site shown in red. Bcl-x splicing reporters with the indicated mutations (mut1–mut5) were
generated.
(B) Binding of Bcl-x pre-mRNAs with RBM4 was detected by RNA immunoprecipitation (IP) assay in cells exogenously expressing FLAG-RBM4 or a vector
control. The binding of Mcl-1 mRNA was used as a specificity control.
(C) 293 cells were cotransfected with FLAG-RBM4 or a vector control and the indicated mutant or wild-type (WT) Bcl-x reporters and then immunoprecipitated
with anti-FLAG antibody. The coprecipitated RNAs were detected by RT-PCR.
(D) 293 cells containing tetracycline-inducible RBM4 or vector control were used to measure Bcl-x splicing. Increased levels of Bcl-xS in uninduced cells were
likely due to expression leakage. The mean ± SD of PSI from triplicate experiments were plotted.
(E) Bcl-x splicing reporters containing variousmutationswere coexpressedwith RBM4 or vector control in 293T cells to assay for the splicing change of Bcl-x. The
mean ± SD of Bcl-xS% was plotted. A representative gel from triplicate experiments is shown.
(F) H157 cells expressing RBM4 or a vector control were used to examine apoptotic markers, including Bcl-xL, cleaved caspase 3 (Casp3), and PARP.
(G) Expression of RBM4 promotes apoptosis. H157 cells expressing RBM4 or controls were stained with propidium iodide, and the apoptotic cells were detected
by flow cytometry. The mean ± SD of the percentage of apoptotic cells from triplicate experiments was plotted.
See also Figure S4.
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not affected by RBM4. Interestingly, coexpression of RBM4
also reduced S6K1 isoform 2 (Figure 6E; Figure S6D), an
SRSF1-activated oncogenic variant that induces cell transfor-
mation by activating the mTOR pathway (Ben-Hur et al., 2013).
In addition, expression of RBM4 alone also inhibits insulin-
induced mTOR activation, as judged by reduced phosphoryla-
tion of S6K1, 4E-BP1, and mTOR itself (Figure 6E). The
phosphorylation of Erk and Akt was not affected, suggesting
that RBM4 controls the downstream stages of mTOR activation.
This observation indicates that RBM4 can also directly inhibit
mTOR activation. Because the mTOR pathway plays key roles
in promoting cell proliferation, inhibition ofmTORbyRBM4prob-
ably contributes to its tumor suppressor activity.
SRSF1 is also predicted to bind the same CGGCGG site in
Bcl-x pre-mRNAs (Figure 4A; Figure S6E), indicating that
RBM4 and SRSF1 may counteract each other in tuning the382 Cancer Cell 26, 374–389, September 8, 2014 ª2014 Elsevier IncBcl-x splicing switch. We coexpressed the Bcl-x splicing re-
porters (wild-type and CGGCGG mutation) with RBM4, SRSF1,
or RBM4/SRSF1. As expected, SRSF1 promoted the antiapop-
totic Bcl-xL isoforms, whereas RBM4 reduced Bcl-xL. In addi-
tion, coexpression of RBM4 can overturn the activity of SRSF1
to increase the proapoptotic Bcl-xS isoform (Figure 6F). Consis-
tently, when the binding site (CGGCGG) was mutated, the
splicing regulation of Bcl-x by both RBM4 and SRSF1 was abol-
ished, confirming that they control Bcl-x splicing by competing
for the same regulatory element.
We further applied colony formation and soft agar assays with
cancer cells expressing SRSF1 and SRSF1/RBM4. Compared
with controls, H157 cells expressing SRSF1 formed more and
larger colonies in both assays, whereas coexpression of RBM4
with SRSF1 significantly reduced colony number and size (Fig-
ure 6G), indicating that RBM4 could inhibit cancer cell prolifera-
tion by antagonizing SRSF1..
Figure 5. RBM4 Regulates Bcl-x Splicing to Inhibit Cancer Progression
(A) H157 cells with stable coexpression of RBM4/Bcl-xL, RBM4/Mcl-1, or RBM4/vector control were generated. Protein expression was confirmed by western
blot analysis. HA, hemagglutinin.
(B) Splicing of Bcl-x in H157 cells expressing RBM4/Bcl-xL, RBM4, RBM4/Mcl-1, or a vector control was measured by semiquantitative RT-PCR. Themean ± SD
of Bcl-xS% from three experiments was plotted. PARP cleavage was examined by western blot analysis.
(C) Colony formation assays using H157 cells expressing RBM4, RBM4/Bcl-xL, RBM4/Mcl-1, or a vector control. Images of the whole plate are shown. Three
experiments were carried out, with mean ± SD of relative colony numbers plotted (p values were determined by Student’s t test). N.S., not significant.
(D)Wound healing assay of H157 cells expressing RBM4, RBM4/Bcl-xL, RBM4/Mcl-1, or a vector control. Themean ± SD of wound closure was plotted (p values
were calculated by Student’s t test). Scale bar, 200 mm.
(E) Xenograft tumors were generated using nude mice injected with H157-luc-control, H157-luc-RBM4/Bcl-xL, or H157-luc-RBM4 cells. Tumors were removed
after 5 weeks, and tumor volume was quantified. The median, upper, and lower quartiles of tumor volume were plotted as a box plot, with whiskers indicating the
data range. The points that are > 1.5 3 interquartile range are marked outliers.
(F and G) H157 cells expressing RBM4 or a vector control were treated with or without the Bcl-xL inhibitor WEHI-539. The resulting cells were analyzed by colony
formation (F) and anchorage-independent growth (G) assays. Three experiments were carried out, with the mean ± SD of relative colony numbers plotted
(p values were calculated by Student’s t test). Images of the whole plate are shown in (F). Scale bars, 100 mm.
(H) Inverse correlation of Bcl-x and RBM4 in lung cancer patients. Oncomine was used to analyze expression data. The mean levels of Bcl-xL and RBM4 were
plotted, and error bars indicate the upper and lower quartiles.
See also Figure S5.
Cancer Cell
RBM4 Inhibits Tumorigenesis via Splicing Control
Cancer Cell 26, 374–389, September 8, 2014 ª2014 Elsevier Inc. 383
Figure 6. RBM4 Antagonizes SRSF1 to Inhibit Cancer Cell Growth
(A) H157 cells expressing RBM4were treatedwith Z-VAD or DMSO control. The apoptotic markers (cleaved PARP and caspase 3) were examined bywestern blot
analysis.
(B) H157 cells expressing RBM4with or without Z-VAD treatment were analyzed by colony formation, soft agar, andwound healing assays. The experiments were
performed in triplicate, and representative pictures are shown. The p values were calculated by Student’s t test. Images of the whole plate are shown in the top
panel. Scale bars, 200 mm.
(legend continued on next page)
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Positively with Survival
To further study the role of RBM4 as a tumor suppressor, we
examined its clinical relevance in cancer patients. We first
analyzed the microarray data set from various large-scale
studies (Buchholz et al., 2005; Finak et al., 2008; Selamat
et al., 2012) and found that tumors collected from NSCLC pa-
tients have a significantly decreased RBM4 level compared
with normal controls (Figure 7A). A similar reduction of RBM4
was also observed in other cancers, including breast and
pancreatic cancer (Figures S7A and S7B), consistent with the
notion that RBM4 is a tumor suppressor in various human
cancers.
Next we surgically collected paired NSCLC samples and adja-
cent normal tissues from seven patients to measure RBM4
levels. We found that, compared with the paired normal tissues,
all seven primary NSCLC specimens had substantially reduced
RBM4 expression in the levels of mRNA and protein (Figures
7B and 7C). This reduction was validated independently by an
immunohistochemistry assay of 110 clinical samples (Figures
7D and 7E).We found that, comparedwith noncancerous tissues
(n = 40), RBM4 was reduced noticeably in both lung squamous
cell carcinoma (n = 30) and adenocarcinoma (n = 40). The
RBM4 staining was undetectable in 57 of 70 (81%) NSCLC sam-
ples, and weak staining was detected in 13 tumors (19%). In
contrast, most normal lung samples (39 of 40) exhibited strong
or weak staining for RBM4.
Compared with paired normal tissues, the splicing of Bcl-x
was shifted in tumor samples, with Bcl-xL being the predominant
isoform (Figure 7F). In addition, the protein levels of Bcl-xL and
SRSF1 were increased substantially in NSCLC samples
compared with paired normal tissues (Figure 7G), further sup-
porting our findings using cultured cancer cells. Taken together,
these clinical observations strongly support the RBM4-mediated
tumor suppression model derived from cell culture and animal
studies.
To further investigate the clinical significance of RBM4 in lung
cancers, we used a survival analysis tool, Kaplan-Meier Plotter,
to analyze the overall survival of cancer patients with different
RBM4 levels using data sets from the Gene Expression Omnibus
(GEO), EGA, and The Cancer Genome Atlas consortia (Gyorffy
et al., 2012). Strikingly, a higher expression of RBM4 was closely
associated with improved overall survival in patients with lung
cancers (Figure 7H), breast cancers (Figure S7C), and ovarian
cancers (Figure S7D), indicating that RBM4might be recognized
as an independent prognostic factor for cancer survival. This
result validated the mechanistic link between reduced expres-
sion of RBM4 and cancer progression, supporting the conclu-(C) H157 cells were transiently transfectedwith increasing amounts of RBM4 and e
A1, and RBM4.
(D) H157 cells expressing SRSF1, SRSF1/RBM4, or a control were collected to e
semiquantitative RT-PCR.
(E) The levels of mTOR and variousmTOR targets were examined in H157 cells exp
Cells expressing RBM4 or a control were also treated with insulin for 30 min to m
(F) Bcl-x splicing reporters (WT and mut4 in Figure 4A) were coexpressed with R
(G) Colony formation and soft agar assays using H157 cells expressing SRSF1, SR
calculated by Student’s t test. Images of the whole plate are shown in the top pa
(B, D, F, and G) Mean ± SD is plotted. See also Figure S6.
Casion that reduced RBM4 expression affects human cancer
progression and patient survival.
DISCUSSION
RBM4 has been reported previously to promote the inclusion of
alternative exons in Tau and a-tropomyosin (Kar et al., 2006; Lin
and Tarn, 2005). Using various reporters, we demonstrate that
RBM4 predominantly functions as a splicing suppressor when
bound directly bound to pre-mRNA. Overexpression of RBM4
in H157 cells inhibited exon inclusion in60% of cassette exons
detected, further supporting RBM4’s role as a splicing suppres-
sor. However, a smaller fraction of AS events are positively regu-
lated by RBM4, and we speculate that the splicing enhancement
by RBM4 is likely a result of complicated mechanisms other than
direct binding between pre-mRNA and RBM4 (such as indirect
effects through other genes or RNA structures or by functioning
together with other splicing factors). For example, RBM4 pro-
moted exon inclusion of RON (Figure 6D; Figure S6C), which is
probably due to an indirect effect resulting from a reduction of
SRSF1 by RBM4.
The N-terminal RNA-binding fragment or C-terminal low-
complexity domain of RBM4 were sufficient to inhibit splicing
from exons, whereas the N-terminal fragment had partial
splicing-inhibitory activity from introns. These results present
an unusual regulatory mode compared with typical splicing fac-
tors. Many splicing factors, like SR proteins, hnRNP A1, and
DAZAP1, contain a separate RNA binding module to recognize
targets and an independent functional module to control splicing
(Choudhury et al., 2014; Del Gatto-Konczak et al., 1999; Grav-
eley and Maniatis, 1998). RBM4 may represent another class in
which both fragments can inhibit splicing but the entire protein
harbors a stronger activity, indicating that the two fragments
cooperatively control splicing rather than function in a modular
fashion.
Besides splicing regulation, RBM4 has also been shown to
regulate translation by suppressing cap-dependent translation
(Lin and Tarn, 2009), activating internal ribosomal entry site-
mediated translation under cell stress (Lin et al., 2007), or medi-
ating an oxygen-regulated translation switch (Uniacke et al.,
2012). As an RNA binding protein shuttling between the nucleus
and cytoplasm, it is possible that RBM4 may affect cell growth
through controlling both translation and splicing. Future investi-
gations should be conducted to determine whether the transla-
tion regulation by RBM4 contributes to its tumor suppression
and how such a process interacts with splicing regulation.
Our results support a model that RBM4 shifts splicing of Bcl-x
to control the balance between pro- and antiapoptotic pathwaysxamined bywestern blot analysis for protein levels of SRSF1, DAZAP1, hnRNP
xamine splicing of the SRSF1 targets BIN1 (left panel) and RON (right panel) by
ressing SRSF1, SRSF1/RBM4, or a control vector using western blot analyses.
easure activation of the mTOR pathway.
BM4, SRSF1, or both to examine their splicing by RT-PCR.
SF1/RBM4, or control. Three experiments were carried out. The p values were
nel. Scale bars, 100 mm.
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Figure 7. RBM4 in NSCLC Patients
(A) RBM4 mRNA levels in lung cancer patients as reported from Oncomine. The median, upper, and lower quartiles were plotted, and the whiskers indicate the
data range. The points that are >1.5 3 interquartile range are marked outliers.
(B) Total RNA isolated from paired NSCLC tumors and adjacent normal tissues were assayed by real-time RT-PCR.
(C) RBM4 levels from seven paired NSCLC tumors (T) and normal (N) tissues were analyzed by western blotting. The p value was calculated by Student’s t test.
Error bars indicate mean ± SD.
(D) Normal lung tissues and NSCLC samples were collected and subjected to immunohistochemical staining with an RBM4 antibody. Scale bar, 40 mm.
(E) Quantification of RBM4 protein levels in normal lung, lung squamous carcinoma, and lung adenocarcinoma. The RBM4 levels were classified into three grades
(negative [], weak positive [+], and strong positive [++]) according to results from immunohistochemical staining.
(F) Splicing of Bcl-x in paired NSCLC tumor (T) and adjacent normal (N) tissue. Error bars indicate mean ± SD.
(G) Protein levels of Bcl-xL and SRSF1 in the paired tumor and adjacent normal tissues.
(H) Kaplan-Meier curve showing overall survival of lung cancer patients with high or low RBM4 expression (p = 3.9 3 1010 by log-rank test).
See also Figure S7.
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the shift of Bcl-x splicing correlates with RBM4 reduction in can-
cer patients, and coexpressing the antiapoptotic variant Bcl-xL
partially reverses the tumor suppression by RBM4 in vitro and
in mouse models. Because the splicing switch of Bcl-x is asso-
ciated with many cancers to protect cancers against apoptotic
signals (Danial, 2007), modulating Bcl-x splicing has been shown
to be a potential therapeutic intervention for cancer (Bauman
et al., 2010; Shkreta et al., 2008; Villemaire et al., 2003).
Other RBM4-regulated events may also contribute to tumor
pathogenesis and progression. With genomic analyses, we
found that RBM4 affected many other AS events in cell meta-
bolism and cell cycle regulation. For example, RBM4 affects
splicing of CD44, which is known to mediate cell migration,
tumor progression, and metastasis (Williams et al., 2013).
Several CD44 splicing variants have been found, with oncogenic
roles in different cancers (Brown et al., 2011; Yae et al., 2012).
These results suggest that RBM4 mediates multiple AS events
critical to cancer progression. As a master regulator of cancer-
related AS, RBM4 potentially inhibits tumorigenesis through
multiple oncogenic pathways, which helps to explain why coex-
pression of Bcl-xL partially reversed the phenotype of restoring
the RBM4 level in cancer.
In addition to regulating oncogenic splicing, RBM4 probably
also inhibits tumor progression by antagonizing SRSF1, which
is known to promote cell proliferation and delay apoptosis. The
reduction of SRSF1 by RBM4 inhibits the oncogenic activity of
several SRSF1 targets, including the proto-oncogene RON and
the tumor suppressor BIN1. More importantly, RBM4 counter-
acts SRSF1 to mediate the activation of the mTORC1 pathway.
Taken together, the antagonism between two splicing factors,
the tumor suppressor RBM4 and the proto-oncogene SRSF1,
presents a delicate functional balance that controls multiple
splicing targets and signaling pathways critical for cancer
proliferation.
Splicing dysregulation has been recognized recently as a
major molecular hallmark of human cancer (David and Manley,
2010; Oltean and Bates, 2013). Some dysregulated AS events
can serve as molecular markers of cancer, whereas others
may be directly responsible for tumorigenesis. Therefore, a
mechanistic study of splicing misregulation would provide new
insights into cancer. This study represents an important example
of how a splicing factor can control critical AS events in cancer
progression. In addition, re-expression of RBM4 can inhibit tu-
mor growth both in a cell culture system and in mouse models,
suggesting that restoration of RBM4 activity may be an attractive
route for future therapy.EXPERIMENTAL PROCEDURES
Cell Culture and Splicing Assay
HEK293T, HeLa, and H157 cells were maintained under standard culture condi-
tions (37C,5%CO2) inculturemediumrecommendedby theATCC.Togenerate
stablecells thatexpressRBM4, theopen reading framewascloned intopcDNA5/
FRT/TO, and the resulting vectorwas cotransfectedwith the pOG44plasmid into
Flp-In T-REx 293 cells (Life Technologies). Similarly, stable H157 cells were
createdusinga lentiviral vector (pCDHcDNAcloningandexpression lentivectors,
System Biosciences). Semiquantitative RT-PCR was performed as described
previously (Wang et al., 2013) and was quantified using Image Quant Software
(GE Healthcare) (see Supplemental Experimental Procedures for more details).CaClinical Tissue Sample Collection
Fresh tumor tissues and normal adjacent tissues were collected from patients
with pathologically and clinically confirmed carcinomas. All human tumor
tissues were obtained with written informed consent from patients or their
guardians prior to participation in the study. The Institutional Review Board
of Dalian Medical University approved the use of the tumor specimens in
this study. Most of tissue samples were fixed in formalin, embedded in
paraffin, and sectioned at 5 mm. One section was stained with hematoxylin
and eosin for histological examination and the others were used for immuno-
histochemistry staining. A portion of tissue specimens was kept in liquid nitro-
gen and sectioned for protein or mRNA extraction.
Xenograft Assays
The Institutional Animal Care and Use Committee of Dalian Medical University
approved the experimental protocols performed on the animals. Female nude
mice were purchased from Vital River Laboratories for subcutaneous xeno-
graft experiments. H157-luc-RBM4 and control cells were injected subcutane-
ously (1 3 106 cells). Tumor size was measured by caliper every 3 days.
RNA-seq Analysis
Cell lines stably expressing RBM4 or a control vector were created, and the to-
tal RNA was purified from the cells using TRIzol reagent. The polyadenylated
RNAs were purified from the cell lines for construction of a sequencing library
using Illumina TruSeq Total RNA sample preparation kits (University of North
Carolina High Throughput Sequencing Facility). The paired-end reads were
generated by the Illumina Hi-Seq 2000 platform and mapped to the human
genome. Changes of splicing isoforms were analyzed by Mixture of Isoforms
pipeline.
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